Article

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancer

2025-12-15

Abstract excerpt

<title>Abstract</title> <p> Background The gut microbiota plays a critical role in modulating the efficacy of immune checkpoint inhibitor (ICI), yet the contribution of the gut virome remains under-characterized, particularly in advanced non-small cell lung cancer (NSCLC). This study aimed to characterize the gut virome and elucidate its mechanistic involvement in response to PD-1 inhibitor therapy. Methods We p...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 34128608-2467-5d2f-a9e2-bdd3d10469e5
DOI: 10.21203/rs.3.rs-8256866/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerDOI 10.21203/rs.3.rs-8256866/v1Read

Metagenomic analysis reveals altered gut virome and diagnostic potential in pancreatic cancerSemantic proximity Read

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read

The Diagnostic Potential & Interactive Dynamics of the Colorectal Cancer ViromeSemantic proximity Read

Gut Metatranscriptomics Based De Novo Assembly Reveals Microbial Signatures Predicting Immunotherapy outcomes in Non-Small Cell Lung CancerSemantic proximity Read

Meta-analysis of fecal metagenomes reveals global viral signatures and its diagnostic potential for colorectal cancer and adenomaSemantic proximity Read

Relationship of The Lung Microbiome With PD-L1 Expression And Immunotherapy Response in Lung CancerSemantic proximity Read

Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefitSemantic proximity Read

Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohortSemantic proximity Read

Human Microbiome as Clinical Biomarkers for Respiratory Tract CancersSemantic proximity Read

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read

Gut Microbiota Signatures with Potential Clinical Usefulness in Colorectal and Non-small Cell Lung CancersSemantic proximity Read